State-of-the-art antibody discovery platform
Over the years, we have continuously improved our antibody discovery platform so that it today stands out as state-of-theart and highly competitive. The platform is based on natural immune responses, which we believe have an unparalleled capacity for antibody diversification and at the same time employ natural tolerance mechanisms to optimize affinity while conserving specificity. We use transgenic rats to provide us with very large fully human antibody repertoires and chickens to provide humanized antibodies against highly conserved targets.
Our efficient lead selection technology
The heart of our antibody discovery platform is Symplex®, which is our proprietary PCR method for cloning all antigen specific antibodies from single sorted B cells purified from animals. Optimized procedures then allow us to express the entire repertoire of full-length antibodies and perform multiparameter screening, which include binding, epitope bin, affinity, function, immunogenicity and quality. Coupled with next generation sequencing this provides us with a six-dimensional property space for each of thousands of antigen specific antibodies from which we can select leads with optimal set of properties.
The productivity of our antibody discovery process is evidenced by the size and diversity of the repertoires of high-quality antibodies from multiple species that we have generated for our partners and internal.
The technology platform may also be used for indications outside of cancer, as demonstrated in our infectious disease partnership with Genentech. We are actively pursuing partnerships in other disease areas to fully utilize our unique and effective integrated R&D platform capable of end-to-end drug development.